HLS Share Price Performance
AU$0
-0.81 (-100.00%)
Price AU$0
Fair ValueAU$0.51
Share Pricen/a
Narrative Update • Jul 24
Healius Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 37 Fair Values set on narratives written by author
HLS Community Narratives
AN
Fair Value
·Fair Value AU$0.51 31.9% undervalued intrinsic discount
Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value AU$0.35 0% overvalued intrinsic discount
Digital And Labor Pressures Will Limit Pathology Margins And Earnings Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value AU$1.05 66.7% undervalued intrinsic discount
Genomic And Specialist Diagnostics Expansion Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Genomic And Specialist Diagnostics Expansion Will Support A Stronger Long Term Outlook
Healius is pushing deeper into advanced genetic and specialist lab tests while rolling out new digital tools and automation to speed up results and cut costs. The upside rests on whether those changes can lift profits despite softer testing demand, wage pressure, and fierce competition for hospital contracts.Read more
AN
AU$1.05
66.7% undervalued intrinsic discount
Fair Value
Profit Margin
3.41%
Future PE
19.43x
Price in 2029
AU$1.43
Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business
Healius is trying to turn its pathology business around by leaning into faster‑growing tests like genomics and by making labs more automated and digital for doctors and patients. The upside comes if these changes lift service quality and costs improve, but it could disappoint if test demand stays weak or wage and funding pressures bite.Read more
AN
AU$0.51
31.9% undervalued intrinsic discount
Fair Value
Profit Margin
1.15%
Future PE
29x
Price in 2029
AU$0.69
Digital And Labor Pressures Will Limit Pathology Margins And Earnings Recovery
Healius is trying to rebuild profits in its pathology business, but rising staff costs, new digital spending, and tighter rules around some tests could make that turnaround harder than many expect. See why newer specialist testing and lab upgrades may not deliver the boost investors are hoping for—and what could prove that worry wrong.Read more
AN
AU$0.35
0% overvalued intrinsic discount
Fair Value
Profit Margin
5%
Future PE
4.64x
Price in 2029
AU$0.48
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
HLS: Potential Agilex Sale Will Reshape Balance Sheet And Future Returns
Fair Value: AU$1.05 66.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLS: Potential Agilex Sale Will Tighten Balance Sheet And Unlock Upside
Fair Value: AU$0.51 31.9% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLS: Potential Agilex Sale And Revised Assumptions Will Shape Future Outlook
Fair Value: AU$0.35 0% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Healius Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 19, 2026
- -0.76
- 30.25%
- -40.09%
- 7.0%
About HLS
- Founded
- 1994
- Employees
- 5962
- CEO
- WebsiteView website
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Recent HLS News & Updates
Narrative Update • Jul 10
HLS: Potential Agilex Sale Will Tighten Balance Sheet And Unlock Upside
Analysts have revised their Healius fair value estimate from A$0.90 to A$0.51. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.
Narrative Update • Jun 26
